ロード中...
Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy
Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzy...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2020-06-01
|
| シリーズ: | BMC Cardiovascular Disorders |
| 主題: | |
| オンライン･アクセス: | http://link.springer.com/article/10.1186/s12872-020-01558-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|